Edge Asset Management Inc. decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.0% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 520,692 shares of the medical instruments supplier’s stock after selling 16,013 shares during the period. Edge Asset Management Inc. owned 0.24% of Becton, Dickinson and worth $95,516,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of BDX. Cohen Lawrence B boosted its stake in Becton, Dickinson and by 39.1% in the first quarter. Cohen Lawrence B now owns 4,272 shares of the medical instruments supplier’s stock worth $784,000 after buying an additional 1,200 shares during the period. Rockland Trust Co. acquired a new stake in Becton, Dickinson and during the first quarter worth approximately $307,000. Wells Fargo & Company MN boosted its stake in Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock worth $602,246,000 after buying an additional 39,362 shares during the period. Integrated Wealth Management boosted its stake in Becton, Dickinson and by 3.4% in the first quarter. Integrated Wealth Management now owns 5,444 shares of the medical instruments supplier’s stock worth $999,000 after buying an additional 181 shares during the period. Finally, Quadrature Capital Ltd acquired a new stake in Becton, Dickinson and during the fourth quarter worth approximately $944,000. Hedge funds and other institutional investors own 75.42% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 205.30 on Friday. The firm has a market capitalization of $43.79 billion, a PE ratio of 34.10 and a beta of 1.05. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $205.73. The company has a 50-day moving average price of $195.21 and a 200 day moving average price of $184.45.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.23 by $0.07. Becton, Dickinson and had a net margin of 10.67% and a return on equity of 25.37%. The company had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.92 billion. During the same period in the prior year, the business posted $2.18 earnings per share. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. On average, equities analysts expect that Becton, Dickinson and Company will post $9.45 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, June 30th. Shareholders of record on Friday, June 9th were given a dividend of $0.73 per share. The ex-dividend date was Wednesday, June 7th. This represents a $2.92 annualized dividend and a yield of 1.42%. Becton, Dickinson and’s payout ratio is currently 48.26%.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/07/22/edge-asset-management-inc-has-95-52-million-position-in-becton-dickinson-and-company-bdx.html.

A number of equities research analysts have recently commented on BDX shares. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $206.00 target price on the stock in a research report on Tuesday, April 11th. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their target price for the company from $210.00 to $180.00 in a research report on Friday, June 30th. BidaskClub upgraded Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. Jefferies Group LLC restated a “buy” rating and set a $200.00 target price on shares of Becton, Dickinson and in a research report on Wednesday, March 29th. Finally, Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and raised their target price for the company from $186.00 to $200.00 in a research report on Monday, April 24th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $194.69.

In other news, VP Jeffrey S. Sherman sold 28,765 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the sale, the vice president now directly owns 70,821 shares in the company, valued at $13,171,289.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.